Indications for: ACCOLATE
Prophylaxis and chronic treatment of asthma.
Adults and Children:
<5yrs: not established. Take 1hr before or 2hrs after meals. 5–11yrs: 10mg twice daily. ≥12yrs: 20mg twice daily.
Hepatic impairment including hepatic cirrhosis.
Not for primary treatment of acute attack. Discontinue if clinical symptoms of liver dysfunction occur; do not resume if confirmed by lab results. Caution when withdrawing from oral steroids. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Leukotriene receptor antagonist.
Potentiates warfarin (monitor PT and adjust warfarin dose). Caution with drugs metabolized by CYP2C9 (eg, tolbutamide, phenytoin, carbamazepine) or CYP3A4 (eg, dihydropyridine calcium channel blockers, cyclosporine, cisapride). Zafirlukast plasma levels reduced by erythromycin, theophylline. Zafirlukast plasma levels increased by aspirin. May increase theophylline levels.
Headache, infection, GI upset, pain, fever; neuropsychiatric events (eg, insomnia, depression); rarely, hepatic dysfunction (esp. in females), agranulocytosis.
Following oral administration of radiolabeled zafirlukast, urinary excretion accounts for approximately 10% of the dose and the remainder is excreted in feces.
In a bioequivalence study, the mean terminal half-life of zafirlukast is approximately 10 hours in both normal adult patients and patients with asthma. In other studies, the mean plasma half-life of zafirlukast ranged from approximately 8 to 16 hours in both normal patients and patients with asthma.
Generic Drug Availability: